Hypogonadism Clinical Trial
Official title:
An Open Label Study to Evaluate the Impact of Novel Fixed-dose Testosterone/Dutasteride Combinations on the Relative Bioavailability of the Individual Dutasteride and Testosterone Components
NCT number | NCT00400335 |
Other study ID # | TDC106222 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | November 14, 2006 |
Last updated | May 31, 2012 |
Start date | October 2006 |
Verified date | February 2011 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone administered with and without dutasteride
Status | Completed |
Enrollment | 60 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion criteria: - Are healthy. - Have a BMI within range of 19-32 kg/m2. - Have not taken dutasteride for one year, or finasteride for the past 3 months. - Have a screening PSA < 2.0ng/mL. Exclusion criteria: - Have had or have breast or prostate cancer, sleep apnea, psychiatric illness, or any other clinically significant current condition. - Have a trigliceride level =500mg/dL. - Have abnormal thyroid or hormone levels. - Would donate more than 500 ML of blood over a 2 month period. - Physician does not think it is a good idea for you to participate in the trial. - Are unwilling to abstain from alcohol during the study. - Have a positive urine drug screen test. - Plan to change your smoking habits during the course of the trial. - Have Hepatitis C, Hepatitis B, or HIV. - Have a lab or ECG abnormality. - Have high or low blood pressure. - Have used of any investigational drug or device during the study or within 30 days prior to 1st dosing of study medication. |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | GSK Investigational Site | Tacoma | Washington |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | lab tests for relative bioavailability of testosterone and dutasteride, | days 1, 2, 3, 19, 20, 21 & 26-31 | ||
Secondary | safety lab tests of various testosterone/dutasteride formulations, | days 1, 2, 3, 19, 20, 21 & 26-31. | ||
Secondary | lab tests for additional pharmacokinetic parameters for testosterone & dutasteride, | days 1, 2, 3, 19, 20, 21 & 26-31. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Withdrawn |
NCT02137265 -
Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism
|
N/A | |
Terminated |
NCT02419105 -
Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors
|
Phase 3 | |
Completed |
NCT02233751 -
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
|
Phase 1 | |
Completed |
NCT02222558 -
Oral Testosterone for the Treatment of Hypogonadism in Males
|
Phase 2 | |
Completed |
NCT01887418 -
Pharmacokinetic Study of Testosterone Enanthate
|
Phase 1/Phase 2 | |
Terminated |
NCT01092858 -
NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
|
Phase 4 | |
Completed |
NCT00624624 -
Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism
|
N/A | |
Completed |
NCT00752869 -
Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement
|
Phase 4 | |
Completed |
NCT00613288 -
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism
|
N/A | |
Completed |
NCT00119483 -
Older Men and Testosterone
|
N/A | |
Completed |
NCT00838838 -
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
|
N/A | |
Completed |
NCT00004438 -
Leuprolide in Treating Adults With Hypogonadotropism
|
N/A | |
Withdrawn |
NCT00398034 -
Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.
|
Phase 2 | |
Completed |
NCT02921386 -
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
|
Phase 2 | |
Completed |
NCT02937740 -
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natestoâ„¢
|
Phase 4 | |
Completed |
NCT01717768 -
Oral Testosterone for the Treatment of Hypogonadism
|
Phase 2 | |
Terminated |
NCT01460654 -
Testosterone and Alendronate in Hypogonadal Men
|
Phase 2 | |
Completed |
NCT00998933 -
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
|
Phase 1 | |
Terminated |
NCT00743327 -
Androgen Deprivation Therapy Study
|
N/A |